VYNE Therapeutics Inc. (NASDAQ:VYNE) went down by -6.56% from its latest closing price compared to the recent 1-year high of $13.20. The company’s stock price has collected -9.52% of loss in the last five trading sessions. Press Release reported on 10/12/21 that Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
Is It Worth Investing in VYNE Therapeutics Inc. (NASDAQ :VYNE) Right Now?
Plus, the 36-month beta value for VYNE is at 0.70.
VYNE currently public float of 44.90M and currently shorts hold a 2.14% ratio of that float. Today, the average trading volume of VYNE was 728.23K shares.
VYNE’s Market Performance
VYNE stocks went down by -9.52% for the week, with a monthly drop of -27.39% and a quarterly performance of -59.29%, while its annual performance rate touched -85.53%. The volatility ratio for the week stands at 7.47% while the volatility levels for the past 30 days are set at 6.25% for VYNE Therapeutics Inc.. The simple moving average for the period of the last 20 days is -15.93% for VYNE stocks with a simple moving average of -75.39% for the last 200 days.
VYNE Trading at -28.74% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.36% of loss for the given period.
Volatility was left at 6.25%, however, over the last 30 days, the volatility rate increased by 7.47%, as shares sank -22.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.32% lower at present.
During the last 5 trading sessions, VYNE fell by -9.52%, which changed the moving average for the period of 200-days by -81.96% in comparison to the 20-day moving average, which settled at $1.3390. In addition, VYNE Therapeutics Inc. saw -81.96% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 12,500 shares at the price of $1.60 back on Aug 25. After this action, LEPORE PATRICK G now owns 50,000 shares of VYNE Therapeutics Inc., valued at $20,000 using the latest closing price.
PERCEPTIVE ADVISORS LLC, the 10% Owner of VYNE Therapeutics Inc., sale 250,000 shares at $1.74 during a trade that took place back on Aug 16, which means that PERCEPTIVE ADVISORS LLC is holding 4,935,057 shares at $435,000 based on the most recent closing price.
Stock Fundamentals for VYNE
Equity return is now at value -138.70, with -72.90 for asset returns.